The Medical Research Council Population Health Research Unit at the University of Oxford, Oxford, UK.
Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
BMC Nephrol. 2023 Oct 25;24(1):310. doi: 10.1186/s12882-023-03339-3.
Large placebo-controlled trials have demonstrated kidney and cardiovascular clinical benefits of SGLT-2 inhibitors. Data from the EMPA-KIDNEY and DELIVER trials and associated meta-analyses triggered an update to the UK Kidney Association Clinical Practice Guideline on Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease. We provide a summary of the full guideline and highlight the rationale for recent updates. The use of SGLT-2 inhibitors in people with specific medical conditions, including type 1 diabetes, kidney transplants, and people admitted to hospital with heart failure is also considered, along with Recommendations for future research and Recommendations for implementation. A full "lay" summary of the guidelines is provided as an appendix to ensure that these guidelines are accessible and understandable to people who are not medical professionals.
大型安慰剂对照试验已经证明 SGLT-2 抑制剂对肾脏和心血管有临床益处。EMPOWER-KIDNEY 和 DELIVER 试验的数据以及相关的荟萃分析促使英国肾脏病协会对成人肾脏疾病中钠-葡萄糖共转运蛋白-2（SGLT-2）抑制剂的临床实践指南进行了更新。我们提供了完整指南的摘要，并强调了最近更新的基本原理。还考虑了 SGLT-2 抑制剂在特定医疗条件下的使用，包括 1 型糖尿病、肾移植和因心力衰竭住院的患者，同时还考虑了对未来研究的建议和实施建议。提供了指南的完整“通俗”摘要作为附录，以确保这些指南对非医疗专业人员来说是可及和易懂的。
